‘Choose your IP armour carefully’: Novartis, HP, Nestlé and Vidal

Companies face increasingly complex decisions over what IP to use, particularly when collaborating. Muireann Bolger hears the dos and don’ts of protection from senior counsel.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Make your voice heard: Call for input on AI, the UPC, and patent trends

4 June 2025 Survey launched ahead of LSIPR’s LSPN Europe conference | Seeks input on AI impact, Brexit, and Unitary Patent system | Focuses on patent challenges in pharma, biotech, medical devices, diagnostics to shape conference discussions in London.

Americas

LSPN: In-house ‘chess game’ is the same, but the rules have changed

9 May 2025 Counsel are using their unique position as the centre of science and law to deliver value far beyond traditional IP protection, finds Marisa Woutersen.

Americas

LSPN: Counsel grapple with AI’s impact on training and critical thinking

8 May 2025 Legal heads from Pfizer and The Broad Institute stress the need for cross-disciplinary teams and careful training as AI software becomes mainstream, reports Marisa Woutersen from LSPN 2025.

More features

Trump threatens 100% tariff hike on pharma imports into the US

Budgets, CRISPR, and keeping pace with tech: top challenges for Europe’s patent pros

EU court delivers verdict on Biogen’s market exclusivity for MS drug

Mewburn expands AI and medtech expertise with London hire

AbbVie faces secrets lawsuit over $2.1bn Capstan deal

All eyes on Squires: What IP experts want from the new USPTO director

Crafting claim strategies in animal and human therapeutics

MSD scores second win in patent fight over Keytruda

‘Choose your IP armour carefully’: Novartis, HP, Nestlé and Vidal

More on this story

Editor's picks

Editor's picks

More features